Colorectal cancer

Dekker, Evelien; Tanis, Pieter J.; Vleugels, Jasper L A; Kasi, Pashtoon Murtaza; Wallace, Michael B.

doi:10.1016/s0140-6736(19)32319-0

Cited by 2,685 publications

(2,037 citation statements)

References 155 publications

Supporting

Mentioning

1,978

Contrasting

Unclassified

Order By: Relevance

“…CRC risk factors include obesity, Western diet, lack of physical activity, excessive alcohol use, hereditary syndromes (e.g., Lynch syndrome), and smoking (223). Treatment includes surgery, combination chemotherapy, radiation therapy, and targeted therapy, including antibodies against VEGF/VEGFR or EGFR (224). Although advances in better screening and treatment have been made in the last decade, long-term survival remains poor for metastatic CRC patients.…”

Section: Colorectal Cancermentioning

confidence: 99%

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

et al. 2020

View full text Add to dashboard Cite

CD73, a cell surface 5 ′ nucleotidase that generates adenosine, has emerged as an attractive therapeutic target for reprogramming cancer cells and the tumor microenvironment to dampen antitumor immune cell evasion. Decades of studies have paved the way for these findings, starting with the discovery of adenosine signaling, particularly adenosine A2A receptor (A2AR) signaling, as a potent suppressor of tissue-devastating immune cell responses, and evolving with studies focusing on CD73 in breast cancer, melanoma, and non-small cell lung cancer. Gastrointestinal (GI) cancers are a major cause of cancer-related deaths. Evidence is mounting that shows promise for improving patient outcomes through incorporation of immunomodulatory strategies as single agents or in combination with current treatment options. Recently, several immune checkpoint inhibitors received FDA approval for use in GI cancers; however, clinical benefit is limited. Investigating molecular mechanisms promoting immunosuppression, such as CD73, in GI cancers can aid in current efforts to extend the efficacy of immunotherapy to more patients. In this review, we discuss current clinical and basic research studies on CD73 in GI cancers, including gastric, liver, pancreatic, and colorectal cancer, with special focus on the potential of CD73 as an immunotherapy target in these cancers. We also present a summary of current clinical studies targeting CD73 and/or A2AR and combination of these therapies with immune checkpoint inhibitors.

show abstract

Section: Colorectal Cancermentioning

confidence: 99%

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In CRC, KRAS and NRAS mutations are found in approximately 44.7% and 7.5% of cases respectively 35 and RAS has not only been found to drive tumour progression but also is key in tumour maintenance [36][37][38] . Lifestyle factors, including smoking, diet, lack of exercise, combined with an aging population all contribute to an increased risk of CRC 39 . A number of advances have been made in recent years to both treatment and diagnosis; however, despite new treatments doubling survival for advanced disease 39 , prognosis for metastatic disease is still poor 40 .…”

Section: Discussionmentioning

confidence: 99%

ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer

et al. 2020

View full text Add to dashboard Cite

The apoptosis-stimulating protein of p53 (ASPP) family of proteins can regulate apoptosis by interacting with the p53 family and have been identified to play an important role in cancer progression. Previously, we have demonstrated that ASPP2 downregulation can promote invasion and migration by controlling β-catenin-dependent regulation of ZEB1, however, the role of ASPP1 in colorectal cancer (CRC) remains unclear. We analyzed data from The Cancer Genome Atlas (TCGA) and coupled this to in vitro experiments in CRC cell lines as well as to experimental pulmonary metastasis in vivo. Tissue microarrays of CRC patients with information of clinical-pathological parameters were also used to investigate the expression and function of ASPP1 in CRC. Here, we report that loss of ASPP1 is capable of enhancing migration and invasion in CRC, both in vivo and in vitro. We demonstrate that depletion of ASPP1 could activate expression of Snail2 via the NF-κB pathway and in turn, induce EMT; and this process is further exacerbated in RAS-mutated CRC. ASPP1 could be a prognostic factor in CRC, and the use of NF-κB inhibitors may provide new strategies for therapy against metastasis in ASPP1-depleted CRC patients.

show abstract

“…Intestinal cancer is the fourth most deadly cancers worldwide [59]. In these cancers, DDX5 is often mutated or overexpressed [60].…”

Section: Discussionmentioning

confidence: 99%

DDX5 targets tissue-specific RNAs to promote intestine tumorigenesis

Abbasi

Long

et al. 2020

Preprint

View full text Add to dashboard Cite

Tumorigenesis in different segments of the intestinal tract involves tissue-specific oncogenic drivers. In the colon, complement component 3 (C3) activation is a major contributor to inflammation and malignancies. By contrast, tumorigenesis in the small intestine involves fatty acid-binding protein 1 (FABP1). However, little is known of the upstream mechanisms driving their expressions in different segments of the intestinal tract. Here, we report that an RNA binding protein DDX5 augments C3 and FABP1 expressions post-transcriptionally to promote tumorigenesis in the colon and small intestine, respectively. Mice with epithelial-specific knockout of DDX5 are protected from intestine tumorigenesis. The identification of DDX5 as the common upstream regulator of tissue-specific oncogenic molecules provides a new therapeutic target for intestine cancers.

show abstract

Colorectal cancer

Cited by 2,685 publications

References 155 publications

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer

DDX5 targets tissue-specific RNAs to promote intestine tumorigenesis

Contact Info

Product

Resources

About